Skip to main content
main-content

Gout and crystal arthropathies

Highlights

10-06-2019 | Gout | Highlight | News

European recommendations for the diagnosis of gout issued

EULAR has issued eight updated evidence-based recommendations to guide the diagnosis of gout.

12-04-2019 | Gout | Editorial | Article

Using genetic studies to assess the impact of hyperuricemia in cardiometabolic and chronic kidney disease

Editorial Board member Fernando Pérez-Ruiz discusses the impact of hyperuricemia in cardiometabolic and chronic kidney disease, focusing on the role of genetic studies in showing a causal association between these conditions.

02-11-2018 | Gout | Highlight | News

Gout patients may benefit from nurse-led care

Nurse-led care involving patient education and engagement increases the likelihood of achieving target serum urate levels among individuals with gout, findings from a UK randomized controlled trial suggest.

18-10-2018 | Crystal arthropathies | Case study | Article

Hyperuricemia and chondrocalcinosis: A clinical challenge for diagnosis and treatment

Editorial board member Fernando Pérez-Ruiz presents an interesting presentation of coexistant hyperuricemia and chondrocalcinosis, and outlines the challenges of diagnosis and management of these conditions.

12-10-2018 | Gout | Highlight | News

Substantial role for diet in gout refuted

A meta-analysis published in The BMJ suggests that diet only explains a small proportion of variation in serum uric acid levels, with genetic variation making a much larger contribution to hyperuricemia risk.

11-10-2018 | Gout | Highlight | News

Allopurinol does not increase CKD risk in patients with gout

Allopurinol, given at a starting dose of at least 300 mg/day, does not increase the risk for chronic kidney disease stage 3 or higher, and may in fact reduce it, in patients with newly diagnosed gout, study data show.

06-09-2018 | Calcium crystal deposition disease | Review | Article

Calcium crystal deposition diseases: Beyond gout

McCarthy GM, Dunne A. Nat Rev Rheumatol 2018. doi: 10.1038/s41584-018-0078-5

21-09-2018 | Gout | Highlight | News

IL-1 beta inhibition reduces gout attack risk

Administration of canakinumab, an interleukin-1β inhibitor, every 3 months is associated with a significantly reduced risk for gout, without lowering serum uric acid levels, shows a secondary exploratory analysis of the CANTOS trial.

04-08-2018 | Gout | Article

Goals of gout treatment: A patient perspective

Singh JA. Clin Rheumatol 2018; 37: 2557–2566. doi: 10.1007/s10067-018-4243-7

05-07-2018 | Gout | Article

Obesity, hypertension and diuretic use as risk factors for incident gout: A systematic review and meta-analysis of cohort studies

The aim of this systematic review and meta-analysis was to assess the risk of incident gout associated with obesity, hypertension and diuretic use.

Evans PL et al. Arthritis Res Ther 2018; 20: 136. doi: 10.1186/s13075-018-1612-1

21-06-2018 | Gout | Review | Article

Predicting response or non-response to urate-lowering therapy in patients with gout

The authors review the extent of treatment success or failure with the xanthine oxidoreductase inhibitors allopurinol and febuxostat and indicate how the dosage of urate-lowering therapy may be modified to increase the response in the majority of patients with gout.

Graham GG et al. Curr Rheumatol Rep 2018; 20: 47. doi: 10.1007/s11926-018-0760-2

22-05-2018 | Gout | Editorial | Article

Audits on gout management: Far from excellence, but working on it

Editorial Board member Fernando Pérez-Ruiz analyzes recent audits on the management of gout in primary and secondary care, and suggests strategies to improve clinical practice.

15-05-2018 | Gout | Highlight | News

‘Reassuring’ findings on fracture risk in patients with gout

Results of a large observational study suggest that patients with gout do not have an elevated risk for fragility fractures.

23-04-2018 | Gout | Highlight | News

Verinurad–febuxostat combination shows promise for the treatment of gout

Results of a phase IIa trial support further investigation of the selective URAT1 inhibitor verinurad in combination with febuxostat for the treatment of gout.

21-02-2018 | Gout | Editorial | Article

Gout therapies and cardiovascular risk

Editorial Board member Fernando Pérez-Ruiz highlights recent clinical trials evaluating the effect of febuxostat on risk of cardiovascular comorbidities, and discusses alternative treatments for gout patients with cardiovascular disease.

30-10-2017 | Gout | Editorial | Article

Evolution or revolution in urate-lowering therapies for gout?

Editorial Board member Fernando Pérez-Ruiz reflects on changing concepts in the understanding of gout, and reviews the latest developments in new urate-lowering medications for the management of gout.

18-07-2017 | Gout | Editorial | Article

The future of gout: Are you ready for it?

Editorial Board member Fernando Pérez-Ruiz discusses the recent increase in gout-related hospitalizations and asks if we are ready for a future of clinical inertia and passivity when it comes to the management of gout.

24-05-2017 | Gout | Editorial | Article

Taking gout seriously

Gout is prevalent in developed countries but does not receive the same investment as conditions such as rheumatoid arthritis. Editorial Board member Fernando Pérez-Ruiz suggests that rheumatologists and healthcare providers need to start taking gout seriously.

Image Credits